Loading...
Despite the increasing number of disease-modifying drugs (DMDs) available for multiple sclerosis (MS), little is known about the prevalence of comorbidities among MS patients and whether these comorbidities are related to disease course and DMD choice, efficacy, and tolerance. To examine these questions, investigators performed a retrospective analysis of prospectively acquired clinical data on patients newly diagnosed with MS since 2010 and their comorbidities at the time of diagnosis. The sample included 1877 patients, which represented about 10% of Italian MS patients diagnosed during this period.
Overall, nearly one quarter of patients had ≥1 comorbidity at diagnosis. Other autoimmune diseases — especially autoimmune thyroid disease, typ…